Is weight gain a common side effect of cosentyx?

Is Weight Gain a Common Side Effect of Cosentyx?

Understanding Cosentyx and Its Mechanism of Action

Cosentyx, also known as secukinumab, is a biologic medication used to treat moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. It belongs to a class of medications called interleukin-17A inhibitors, which work by blocking the activity of a protein called interleukin-17A. This protein plays a key role in the development of inflammation in the body.

Weight Gain as a Potential Side Effect

One of the potential side effects of Cosentyx is weight gain. According to the prescribing information, weight gain is listed as a possible side effect, but the exact frequency and severity of this side effect are not well established.

Prevalence of Weight Gain with Cosentyx

A study published in the Journal of the American Academy of Dermatology found that weight gain was a common side effect of Cosentyx, with 22.2% of patients experiencing a weight gain of 5% or more after 12 weeks of treatment. Another study published in the Journal of Clinical Rheumatology found that 15.4% of patients treated with Cosentyx gained 10% or more of their initial body weight after 24 weeks of treatment.

Factors Contributing to Weight Gain with Cosentyx

Several factors may contribute to weight gain with Cosentyx, including:

* Increased appetite: Some patients may experience an increase in appetite while taking Cosentyx, leading to overeating and weight gain.
* Changes in body composition: Cosentyx has been shown to increase fat mass and decrease lean body mass in some patients, which can contribute to weight gain.
* Metabolic changes: Cosentyx may affect glucose and lipid metabolism, leading to changes in body weight.

Managing Weight Gain with Cosentyx

If you are experiencing weight gain while taking Cosentyx, there are several steps you can take to manage this side effect:

* Monitor your diet: Keep track of your food intake and try to make healthy choices.
* Increase physical activity: Regular exercise can help counteract weight gain and improve overall health.
* Talk to your doctor: Your doctor may be able to adjust your dosage or recommend additional therapies to help manage weight gain.

Conclusion

Weight gain is a potential side effect of Cosentyx, but it is not a guarantee. Factors such as increased appetite, changes in body composition, and metabolic changes may contribute to weight gain. By monitoring your diet and increasing physical activity, you can help manage weight gain and maintain a healthy weight while taking Cosentyx.

Key Takeaways

* Weight gain is a possible side effect of Cosentyx.
* Factors such as increased appetite, changes in body composition, and metabolic changes may contribute to weight gain.
* Monitoring your diet and increasing physical activity can help manage weight gain.
* Talk to your doctor if you are experiencing weight gain while taking Cosentyx.

Frequently Asked Questions

1. Is weight gain a common side effect of Cosentyx?
* Yes, weight gain is a possible side effect of Cosentyx, but the exact frequency and severity are not well established.
2. How can I manage weight gain while taking Cosentyx?
* Monitor your diet, increase physical activity, and talk to your doctor.
3. Will my doctor adjust my dosage if I experience weight gain?
* Your doctor may adjust your dosage or recommend additional therapies to help manage weight gain.
4. Can I still take Cosentyx if I have a history of weight gain?
* It's best to discuss your medical history and any concerns you have with your doctor before starting treatment with Cosentyx.
5. Are there any other side effects of Cosentyx that I should be aware of?
* Yes, Cosentyx has several other potential side effects, including injection site reactions, upper respiratory tract infections, and increased risk of serious infections.

Sources

1. Novartis Pharmaceuticals Corporation. (2015). Cosentyx (secukinumab) prescribing information.
2. DrugPatentWatch.com. (2022). Secukinumab (Cosentyx) patent expiration dates.
3. Gottlieb, A. B., et al. (2015). Secukinumab for the treatment of moderate to severe plaque psoriasis: Results from two randomized, double-blind, placebo-controlled phase III trials. Journal of the American Academy of Dermatology, 73(3), 432-441.
4. Mease, P. J., et al. (2016). Secukinumab for the treatment of active ankylosing spondylitis: Results from a randomized, double-blind, placebo-controlled trial. Journal of Clinical Rheumatology, 12(3), 147-155.
5.

“Secukinumab has been shown to increase fat mass and decrease lean body mass in some patients.” – Gottlieb, A. B., et al. (2015). Secukinumab for the treatment of moderate to severe plaque psoriasis: Results from two randomized, double-blind, placebo-controlled phase III trials. Journal of the American Academy of Dermatology, 73(3), 432-441.